NARA Discovery
Article Details
← Back to Search Results
Journal Article

Co‐Infection with Pseudomonas anguilliseptica and Delftia acidovorans in the European eel, Anguilla anguilla (L.): a case history of an illegally trafficked protected species

K B Andree; C J Rodgers; D Furones; E Gisbert
Journal of Fish Diseases · Vol. 36, Issue 7 · pp. 647-656 · 2013

Abstract

Inspections by customs agents at Barcelona airport discovered 420 kg of contraband glass eels prepared for shipment to Hong Kong. After confiscation of these animals by police, they were transported to holding facilities to be maintained until after a judicial hearing. Upon arrival, they were separated into two groups and held under ambient flow‐through conditions in fresh water. During their captivity period, several peaks in mortality occurred and multiple bacterial strains were isolated from moribund animals. Sequencing of 16S rDNA was used to determine specific identity of the isolates. An initial isolation of Pseudomonas anguilliseptica was treated with oxytetracycline. A subsequent isolation of Delftia acidovorans proved resistant to oxytetracycline and was treated with gentamicin in combination with sulphadiazine–trimethoprim. Once the health condition of the animals was stabilized, they were partitioned into groups and subsequently released as part of a restocking effort for the species following the guidelines of Regulation (EC) 1100/2007 (Anon 2007). This represents the first record for both bacterial species in the host Anguilla anguilla in the Spanish Mediterranean.

Bibliographic Information

JournalJournal of Fish Diseases
PublisherWiley
Publication Date2013-07-01
Publication Year2013
Volume36
Issue7
Pages647-656
Document TypeJournal Article
Print ISSN0140-7775
eISSN1365-2761
DOI10.1111/jfd.12066
SubjectGeneral Aquaculture, Fisheries & Fish Science

Access Information

NARA Access Coverage1997-01-01~Current
Journal Homepagehttps://onlinelibrary.wiley.com/loi/13652761
Publisher PageOpen Publisher Page
Full-text access depends on NARA's subscribed coverage and institutional access.